Injection Pen Market is expected to reach a valuation of US$ 85.8 billion by 2033 | FMI

 The global Injection Pen Market is anticipated to create a positive outlook for the market by registering a CAGR of 7.0% from 2022 to 2033. The global market is expected to reach a market valuation of US$ 85.8 billion by the end of 2033, up from the US$ 40.7 billion that was recorded for 2022.

As per the historical analysis, Future Market Insights registered a CAGR of 6.4% from 2017 to 2022 and reached a market value of US$ 40.7 billion in 2022. Due to a significant rise in the incidence of needle sticks, there is a greater demand for injection pens over conventional vial and needle procedures, which is encouraging the market to grow.

To learn more about this report @ https://www.futuremarketinsights.com/reports/injection-pen-market

Surging numbers of chronic diseases, favorable reimbursement, and support from the government are expected to drive market growth. Furthermore, a growing number of regulatory approvals and technological advancements in the injectable pens market are predicted to augment growth in the market. Diabetes is considered the primary cause of death all over the world. As a result, the market for injection pens is being driven by the rising number of diabetic patients of all ages around the world as well as the ease of use and accuracy of insulin doses. As per the estimations by World Health Organization, injection pens are considered the ideal option as chronic conditions require frequent medication administration. 

Injection pens have drastically replaced other delivery methods for injectable medications as the primary standard. Their popularity has surged significantly as a result of their convenience and ability to be administered directly by the patient without a medical professional's assistance. Technological developments comprise a cap for insulin pens with a sensor to monitor pen usage temperature. The insulin pen adaptor has a capability that can scan an object and determine the amount of insulin present. The affordable pricing of injection pens makes them more accessible to people of all ages and geographies. Most injectable pens fall into two categories, reusable injection pens or disposable injection pens. A large number of patients prefer using prefilled injectable pens, which are disposable, to administer medications because of their convenience.

Key Takeaways

  • The growing geriatric population worldwide is anticipated to create robust growth opportunities for the Needle pen market across the projection period. With aging, a rapid decrease in overall immunity is visible, resulting in several health issues in individuals including chronic diseases such as cardiovascular diseases and diabetes.
  • According to the estimations conducted by the World Health Organization, it estimated that around 80% of older people would reside in low-and-middle-income nations. The population is aging considerably more quickly over the past few years.
  • In 2020, there were more individuals over the age of 60 than under five-year-old. The number of individuals over 60 in the world will increase from 12% to 22% between 2015 and 2050.
  • The global injection pen market is expanding as a result of rising healthcare expenditure and increased public awareness of the availability of novel and convenient injection pens. In addition to that, increased prevalence of chronic diseases like cancer and autoimmune diseases. The International Agency for Research on Cancer stated that there were about more than 19.3 million cancer cases and 10 million cancer-related deaths worldwide in 2020.

Competitive Landscape

The Needle-free injector market is known as a highly competitive market and consists of numerous established companies. To increase their position in the market, key players have been adopting methods such as product launches and certification/ product approvals for a new products.

Key Market Players:

  • Novo Nordisk A/S
  • Medtronic plc
  • Becton, Dickinson and Company
  • Sanofi
  • Eli Lilly and Company
  • Merck
  • AstraZeneca
  • Hoffmann-La Roche Ltd.
  • Owen Mumford Ltd
  • Ypsomed AG
  • Terumo Medical Corporation
  • Braun Medical
  • Sun Pharmaceutical Industries Ltd.

Key Segments Covered in Injection Pen Industry Research

By Product:

  • Disposable Injection Pens
  • Reusable Injection Pens

By Indication:

  • Anaphylaxis
  • Diabetes
  • Cardiovascular Diseases
  • Multiple Sclerosis
  • Rheumatoid Arthritis
  • Cancer
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more